Pan-ebolavirus protective therapy by two multifunctional human antibodies

Pavlo Gilchuk; Charles D. Murin; Robert W. Cross; Philipp A. Ilinykh; Kai Huang; Natalia Kuzmina; Viktoriya Borisevich; Krystle N. Agans; Joan B. Geisbert; Seth J. Zost; Rachel S. Nargi; Rachel E. Sutton; Naveenchandra Suryadevara; Robin G. Bombardi; Robert H. Carnahan; Alexander Bukreyev; Thomas W. Geisbert; Andrew B. Ward; James E. Crowe

doi:10.1016/j.cell.2021.09.035

Pan-ebolavirus protective therapy by two multifunctional human antibodies

Pavlo Gilchuk, Charles D. Murin, Robert W. Cross, Philipp A. Ilinykh, Kai Huang, Natalia Kuzmina, Viktoriya Borisevich, Krystle N. Agans, Joan B. Geisbert, Seth J. Zost, Rachel S. Nargi, Rachel E. Sutton, Naveenchandra Suryadevara, Robin G. Bombardi, Robert H. Carnahan, Alexander Bukreyev, Thomas W. Geisbert, Andrew B. Ward, James E. Crowe

Pathology

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Ebolaviruses cause a severe and often fatal illness with the potential for global spread. Monoclonal antibody-based treatments that have become available recently have a narrow therapeutic spectrum and are ineffective against ebolaviruses other than Ebola virus (EBOV), including medically important Bundibugyo (BDBV) and Sudan (SUDV) viruses. Here, we report the development of a therapeutic cocktail comprising two broadly neutralizing human antibodies, rEBOV-515 and rEBOV-442, that recognize non-overlapping sites on the ebolavirus glycoprotein (GP). Antibodies in the cocktail exhibited synergistic neutralizing activity, resisted viral escape, and possessed differing requirements for their Fc-regions for optimal in vivo activities. The cocktail protected non-human primates from ebolavirus disease caused by EBOV, BDBV, or SUDV with high therapeutic effectiveness. High-resolution structures of the cocktail antibodies in complex with GP revealed the molecular determinants for neutralization breadth and potency. This study provides advanced preclinical data to support clinical development of this cocktail for pan-ebolavirus therapy.

Original language	English (US)
Pages (from-to)	5593-5607.e18
Journal	Cell
Volume	184
Issue number	22
DOIs	https://doi.org/10.1016/j.cell.2021.09.035
State	Published - Oct 28 2021

Keywords

Ebolavirus
antibody therapeutics
ebolavirus infection
epitope mapping
glycoprotein
neutralizing antibodies
viral antibodies

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2021.09.035

Cite this

Gilchuk, P., Murin, C. D., Cross, R. W., Ilinykh, P. A., Huang, K., Kuzmina, N., Borisevich, V., Agans, K. N., Geisbert, J. B., Zost, S. J., Nargi, R. S., Sutton, R. E., Suryadevara, N., Bombardi, R. G., Carnahan, R. H., Bukreyev, A., Geisbert, T. W., Ward, A. B., & Crowe, J. E. (2021). Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell, 184(22), 5593-5607.e18. https://doi.org/10.1016/j.cell.2021.09.035

Gilchuk, P, Murin, CD, Cross, RW, Ilinykh, PA, Huang, K, Kuzmina, N, Borisevich, V, Agans, KN, Geisbert, JB, Zost, SJ, Nargi, RS, Sutton, RE, Suryadevara, N, Bombardi, RG, Carnahan, RH, Bukreyev, A , Geisbert, TW, Ward, AB & Crowe, JE 2021, 'Pan-ebolavirus protective therapy by two multifunctional human antibodies', Cell, vol. 184, no. 22, pp. 5593-5607.e18. https://doi.org/10.1016/j.cell.2021.09.035

@article{08197500f2a24638b6e64106697cf37b,

title = "Pan-ebolavirus protective therapy by two multifunctional human antibodies",

abstract = "Ebolaviruses cause a severe and often fatal illness with the potential for global spread. Monoclonal antibody-based treatments that have become available recently have a narrow therapeutic spectrum and are ineffective against ebolaviruses other than Ebola virus (EBOV), including medically important Bundibugyo (BDBV) and Sudan (SUDV) viruses. Here, we report the development of a therapeutic cocktail comprising two broadly neutralizing human antibodies, rEBOV-515 and rEBOV-442, that recognize non-overlapping sites on the ebolavirus glycoprotein (GP). Antibodies in the cocktail exhibited synergistic neutralizing activity, resisted viral escape, and possessed differing requirements for their Fc-regions for optimal in vivo activities. The cocktail protected non-human primates from ebolavirus disease caused by EBOV, BDBV, or SUDV with high therapeutic effectiveness. High-resolution structures of the cocktail antibodies in complex with GP revealed the molecular determinants for neutralization breadth and potency. This study provides advanced preclinical data to support clinical development of this cocktail for pan-ebolavirus therapy.",

keywords = "Ebolavirus, antibody therapeutics, ebolavirus infection, epitope mapping, glycoprotein, neutralizing antibodies, viral antibodies",

author = "Pavlo Gilchuk and Murin, {Charles D.} and Cross, {Robert W.} and Ilinykh, {Philipp A.} and Kai Huang and Natalia Kuzmina and Viktoriya Borisevich and Agans, {Krystle N.} and Geisbert, {Joan B.} and Zost, {Seth J.} and Nargi, {Rachel S.} and Sutton, {Rachel E.} and Naveenchandra Suryadevara and Bombardi, {Robin G.} and Carnahan, {Robert H.} and Alexander Bukreyev and Geisbert, {Thomas W.} and Ward, {Andrew B.} and Crowe, {James E.}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = oct,

day = "28",

doi = "10.1016/j.cell.2021.09.035",

language = "English (US)",

volume = "184",

pages = "5593--5607.e18",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "22",

}

TY - JOUR

T1 - Pan-ebolavirus protective therapy by two multifunctional human antibodies

AU - Gilchuk, Pavlo

AU - Murin, Charles D.

AU - Cross, Robert W.

AU - Ilinykh, Philipp A.

AU - Huang, Kai

AU - Kuzmina, Natalia

AU - Borisevich, Viktoriya

AU - Agans, Krystle N.

AU - Geisbert, Joan B.

AU - Zost, Seth J.

AU - Nargi, Rachel S.

AU - Sutton, Rachel E.

AU - Suryadevara, Naveenchandra

AU - Bombardi, Robin G.

AU - Carnahan, Robert H.

AU - Bukreyev, Alexander

AU - Geisbert, Thomas W.

AU - Ward, Andrew B.

AU - Crowe, James E.

PY - 2021/10/28

Y1 - 2021/10/28

N2 - Ebolaviruses cause a severe and often fatal illness with the potential for global spread. Monoclonal antibody-based treatments that have become available recently have a narrow therapeutic spectrum and are ineffective against ebolaviruses other than Ebola virus (EBOV), including medically important Bundibugyo (BDBV) and Sudan (SUDV) viruses. Here, we report the development of a therapeutic cocktail comprising two broadly neutralizing human antibodies, rEBOV-515 and rEBOV-442, that recognize non-overlapping sites on the ebolavirus glycoprotein (GP). Antibodies in the cocktail exhibited synergistic neutralizing activity, resisted viral escape, and possessed differing requirements for their Fc-regions for optimal in vivo activities. The cocktail protected non-human primates from ebolavirus disease caused by EBOV, BDBV, or SUDV with high therapeutic effectiveness. High-resolution structures of the cocktail antibodies in complex with GP revealed the molecular determinants for neutralization breadth and potency. This study provides advanced preclinical data to support clinical development of this cocktail for pan-ebolavirus therapy.

AB - Ebolaviruses cause a severe and often fatal illness with the potential for global spread. Monoclonal antibody-based treatments that have become available recently have a narrow therapeutic spectrum and are ineffective against ebolaviruses other than Ebola virus (EBOV), including medically important Bundibugyo (BDBV) and Sudan (SUDV) viruses. Here, we report the development of a therapeutic cocktail comprising two broadly neutralizing human antibodies, rEBOV-515 and rEBOV-442, that recognize non-overlapping sites on the ebolavirus glycoprotein (GP). Antibodies in the cocktail exhibited synergistic neutralizing activity, resisted viral escape, and possessed differing requirements for their Fc-regions for optimal in vivo activities. The cocktail protected non-human primates from ebolavirus disease caused by EBOV, BDBV, or SUDV with high therapeutic effectiveness. High-resolution structures of the cocktail antibodies in complex with GP revealed the molecular determinants for neutralization breadth and potency. This study provides advanced preclinical data to support clinical development of this cocktail for pan-ebolavirus therapy.

KW - Ebolavirus

KW - antibody therapeutics

KW - ebolavirus infection

KW - epitope mapping

KW - glycoprotein

KW - neutralizing antibodies

KW - viral antibodies

UR - http://www.scopus.com/inward/record.url?scp=85117837337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117837337&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2021.09.035

DO - 10.1016/j.cell.2021.09.035

M3 - Article

C2 - 34715022

AN - SCOPUS:85117837337

SN - 0092-8674

VL - 184

SP - 5593-5607.e18

JO - Cell

JF - Cell

IS - 22

ER -

Pan-ebolavirus protective therapy by two multifunctional human antibodies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this